header advert
Results 1 - 4 of 4
Results per page:
Applied filters
Content I can access

Hip

Include Proceedings
Dates
Year From

Year To
Orthopaedic Proceedings
Vol. 106-B, Issue SUPP_6 | Pages 22 - 22
2 May 2024
Logishetty K Whitwell D Palmer A Gundle R Gibbons M Taylor A Kendrick B
Full Access

There is a paucity of data available for the use of Total Femoral Arthroplasty (TFA) for joint reconstruction in the non-oncological setting. The aim of this study was to evaluate TFA outcomes with minimum 5-year follow-up.

This was a retrospective database study of TFAs performed at a UK tertiary referral revision arthroplasty unit. Inclusion criteria were patients undergoing TFA for non-oncological indications. We report demographics, indications for TFA, implant survivorship, clinical outcomes, and indications for re-operation.

A total of 39 TFAs were performed in 38 patients between 2015–2018 (median age 68 years, IQR 17, range 46–86), with 5.3 years’ (IQR 1.2, 4.1–18.8) follow-up; 3 patients had died. The most common indication (30/39, 77%) for TFA was periprosthetic joint infection (PJI) or fracture-related infection (FRI); and 23/39 (59%) had a prior periprosthetic fracture (PPF). TFA was performed with dual-mobility or constrained cups in 31/39 (79%) patients. Within the cohort, 12 TFAs (31%) required subsequent revision surgery: infection (7 TFAs, 18%) and instability (5 TFAs, 13%) were the most common indications. 90% of patients were ambulatory post-TFA; 2 patients required disarticulation due to recurrent PJI. While 31/39 (79%) were infection free at last follow-up, the remainder required long-term suppressive antibiotics.

This is the largest series of TFA for non-oncological indications. Though TFA has inherent risks of instability and infection, most patients are ambulant after surgery. Patients should be counselled on the risk of life-long antibiotics, or disarticulation when TFA fails.


Orthopaedic Proceedings
Vol. 101-B, Issue SUPP_6 | Pages 40 - 40
1 May 2019
Vanhegan I Martin A Gundle R Taylor A Kendrick B
Full Access

Introduction

We are a high-volume arthroplasty unit performing over 800 primary THRs annually at an approximate reimbursement of £6.5 million to the Trust. 70% are hybrid and we have been using the Taperfit - Trinity combination (Corin, Cirencester) since March 2016. We aimed to investigate the potential cost-savings and clinical benefits of instrument rationalisation using this system following GIRFT principles.

Methods

Taperfit (ODEP 10A) is a polished, collarless, double tapered stem available in multiple sizes/offsets. Trinity is a hemispherical porous titanium cementless shell. A prospective audit of implant size was performed for the first 50 cases. Based on these findings, instruments were reduced to a single tray per component based on predicted size, named ‘Corin Hip for the Osteoarthritic Patient’ (CHOP). A further re-audit was performed to confirm correct tray constituent sizes. Financial data were calculated using known TSSU costs of approximately £50 per tray.


Orthopaedic Proceedings
Vol. 98-B, Issue SUPP_11 | Pages 49 - 49
1 Jun 2016
Spiegelberg B Kendrick B Taylor A Stubbs D McLardy-Smith P Gundle R
Full Access

Introduction

Native hip joint infection can result in hip arthrosis as a complication requiring the need for subsequent arthroplasty. There is little evidence to support single or staged THA. We present the results of patients who have undergone total hip arthroplasty (THA) following hip joint sepsis in our institution.

Methods

Patients receiving a THA following previous hip joint sepsis between 2003 and 2015 were identified from the operative records database. Further clinical information was collected from the medical records, including timing of infection and surgery, as well as culture results. Functional outcome (Oxford Hip Score, OHS) and patient satisfaction scores (PSS) were recorded.


Orthopaedic Proceedings
Vol. 98-B, Issue SUPP_11 | Pages 52 - 52
1 Jun 2016
Grammatopoulos G Kendrick B Glyn-Jones S McLardy-Smith P Taylor A Gundle R
Full Access

Introduction

The value of Debridement-Antibiotics-and-Implant-Retention (DAIR) in prosthetic-joint-infection (PJI) is still a matter of debate as most studies to-date are underpowered with variable end-points. In our, tertiary referral, bone infection unit we consider DAIR to be a suitable option in all PJIs with soundly fixed prostheses, despite chronicity. The aims of this study were to define the long-term outcome following DAIR in hip PJI and identify factors that influence it.

Methods

This is a retrospective consecutive case series of DAIRs performed between 1997 and 2013. Only infected cases confirmed by established criteria were included. Data recorded included patient demographics, medical history (ASA grade, Charlson and KLICC scores), type of surgery performed (DAIR or DAIR + exchange of modular components) and organism grown. Outcome measures included complications, implant survivorship and functional outcome (Oxford Hip Score, OHS).